Target intelligence / Profile preview

V-type proton ATPase 116 kDa subunit a isoform 3 (TCIRG1)

Target
TCIRG1
Molecular classification
Enzyme, Transporter, Receptor
01

Overview

T-cell immune response cDNA 7 (TIRC7) is an alternative splice variant of the T-cell immune regulator 1 (TCIRG1) gene, which also encodes the a3 subunit of the vacuolar H+-ATPase (V-ATPase) proton pump. While the full-length isoform (OC116) is highly expressed in osteoclasts and is essential for bone resorption and acidification, the N-terminally truncated TIRC7 isoform is transiently expressed on the cell surface of activated T and B lymphocytes, monocytes, and regulatory T cells (Tregs). TIRC7 acts as an immune checkpoint receptor that co-localizes with the T-cell receptor (TCR) and CTLA-4 within the immunological synapse. Upon binding to its natural ligand, the non-polymorphic alpha 2 domain of HLA-DR (HLA-DRα2), TIRC7 delivers inhibitory signals that suppress lymphocyte activation, decrease pro-inflammatory Th1/Th17 cytokine secretion (such as IL-2 and IFN-gamma), and promote T-cell anergy or apoptosis. Consequently, TIRC7 is a promising therapeutic target for modulating immune responses in transplantation, graft-versus-host disease (aGVHD), and autoimmune disorders like rheumatoid arthritis. Monoclonal antibodies such as neliximab and metiliximab have been developed to target TIRC7 to induce immunotolerance, while bisphosphonates like tiludronic acid target the osteoclastic V-ATPase containing this subunit to treat bone resorption disorders.

Other names
T-cell immune response cDNA 7TIRC7T-cell immune regulator 1T-cell immune response cDNA7 proteinVacuolar proton translocating ATPase 116 kDa subunit a isoform 3Osteoclastic proton pump 116 kDa subunitOC116ATP6V0A3ATP6N1CAtp6iOPTB1
02

Mechanism of action

Neliximab and metiliximab are monoclonal antibodies that target the extracellular domain of TIRC7 (the immune-specific isoform of TCIRG1) on activated lymphocytes, modulating T-cell activation, inhibiting the secretion of pro-inflammatory cytokines (such as IL-2 and IFN-gamma), and promoting immunotolerance or apoptosis. Tiludronic acid is a bisphosphonate that inhibits the osteoclastic vacuolar H+-ATPase (V-ATPase) proton pump containing the a3 subunit, preventing the acidification of the bone-osteoclast interface and thereby inhibiting bone resorption.

03

Biological functions

Immune responseSignal transductionApoptosisCell proliferationIon transportBone resorption
04

Disease associations

InflammationAutoimmune diseaseGraft rejectionGraft-versus-host diseaseCancerOsteopetrosis
05

Safety considerations

Systemic immunosuppression and increased risk of infections due to T-cell inhibitionImpaired bone remodeling or osteopetrosis-like skeletal abnormalities due to V-ATPase inhibition in osteoclastsPotential hematological toxicities such as neutropenia, as heterozygous mutations in TCIRG1 are linked to severe congenital neutropeniaRisk of autoimmune hyperactivation or graft-versus-host disease if TIRC7 inhibitory signaling is inadvertently blocked
06

Interacting drugs

Neliximab

2 more in the full profile.

07

Biomarkers

TIRC7 expression levels (mRNA or cell surface protein)FoxP3 expressionCD20 expressionPlatelet countPro-inflammatory cytokine levels (IL-2, IFN-gamma)IL-10 levels

Beyond the preview

Go deeper on V-type proton ATPase 116 kDa subunit a isoform 3 (TCIRG1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on V-type proton ATPase 116 kDa subunit a isoform 3 (TCIRG1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call